Annovis Bio, Inc.
corporate_fare Company Profile
Annovis Bio, Inc. (NYSE:ANVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ANVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ANVS spans 8-K, 4, 424B5, DEFA14A.
Recent high-impact activity:
- FDA Backs Pooling Alzheimer's and Parkinson's Safety Data for Buntanetap NDA
- Second Positive DSMB Safety Nod Keeps Phase 3 Alzheimer's Trial on Track
- Annovis Q3 Loss Widens as R&D Hits $15.8M; DUET-AD Data Due March 2027
- Director Hoffman Buys $5M of Annovis Offering — 5M Shares Plus 5M Warrants at $1.00
- Annovis Prices $21M Stock-and-Warrant Offering at $1.00, a Premium to the $0.87 Market Price
Financial Snapshot
Short Interest & Short Volume
6.77 days to coverFINRA reported short interest of 5,356,098 shares in ANVS as of the October 30, 2026 settlement, a 6.4% decrease from the prior period — about 6.8 days to cover at its recent average daily volume. On November 20, 2026, 59.7% of ANVS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ANVS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.
Final Terms Confirmed for $21.0M Offering · Net Proceeds of About $19.6M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →